Looking at what we know about collagen deposition, TGF-β signaling, hypoxia, and macrophage crosstalk driving adipose fibrosis, I've come to think that YAP/TAZ mechanotransduction sits at the top of this cascade—acting as a master switch that kicks off fibrotic remodeling before inflammation ever shows up. If this holds up, it's a genuinely new therapeutic angle for tackling established fibrosis.

How This Might Work

Sun et al. described the foreign body reaction with macrophage giant cells forming around adipocytes, but nobody's nailed down what actually triggers that response. Here's my take: as adipocytes expand, they pull against the surrounding extracellular matrix, generating mechanical tension that switches on YAP/TAZ in both the adipocytes themselves and nearby stromal cells. Once activated, this creates a self-perpetuating loop where mechanical stress keeps feeding fibrotic changes.

When adipocytes hypertrophy during early obesity or aging, they bump up against physical constraints from the ECM—that's the tension that drives YAP/TAZ into the nucleus, where it turns on collagen I, III, and VI, α-SMA, and TGF-β. The kicker is that YAP/TAZ activation in adipocytes also sparks production of inflammatory cytokines (IL-6, TNF-α) and chemokines like CCL2 that bring in macrophages. So the fibrosis signaling actually comes first, then inflammation follows.

What We Could Test

1. Timing: In diet-induced obesity mouse models, I'd expect to see YAP/TAZ showing up in adipocyte and stromal cell nuclei within 2-4 weeks—well before we see meaningful macrophage infiltration (CD68+ cells) or collagen deposition. That would prove fibrosis comes before inflammation.

2. Blocking it: Knocking down YAP/TAZ specifically in adipocytes using adipoq-Cre should stop TGF-β activation, collagen buildup, and macrophage recruitment even if the adipocytes keep expanding. That would confirm YAP/TAZ as the upstream driver.

3. Reversing established fibrosis: Using verteporfin or peptide inhibitors to block YAP/TAZ in mice that already have obesity-induced fibrosis (16 weeks on HFD) should reverse collagen VI deposition, let adipocytes expand again, shrink those necrotic cores, and improve insulin sensitivity. This addresses the reversibility problem that Cao et al. highlighted.

4. Depot differences: The reason subcutaneous and omental fat respond differently probably comes down to baseline tissue stiffness and YAP/TAZ activation thresholds. Omental depots seem to have lower basal YAP/TAZ activity but greater angiogenic capacity, likely through different Hippo pathway control.

Why This Matters

This idea ties the foreign body reaction model together with mechanobiology in a way that explains why adipocyte death triggers fibrosis and why different fat depots behave differently—it's not just about immune cells, it's about the physical environment. It directly answers whether fibrosis precedes inflammation (yes, via mechanical activation) and points to YAP/TAZ as a way to actually reverse fibrosis once it's established. That's a real gap in how we treat metabolic dysfunction, especially in aging.